Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Roivant Sciences Ltd./ DEFA14A

SEC Filing · DEFA14A

Roivant Sciences Ltd.

SEC Filing

Filed Jul 29, 2026Accepted Jul 29, 2026, 7:00 AM EDTCIK 1635088Accession 0001140361-26-029956
View company →Permanent SEC source ↗
Share

Company context

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Current securities

ROIVNASDAQ · EQUITY · Current
Historical securities (3)
ROIVNASDAQ · EQUITY · Historical · closed Sep 30, 2021ROIVNASDAQ · EQUITY · Historical · closed Oct 19, 2026ROIVWNASDAQ · WARRANT · Historical · closed Sep 1, 2023

Recent company filings

  1. 4 filingOct 27, 2026
  2. SCHEDULE 13G/A - filed by BlackRock, Inc. regarding Roivant Sciences Ltd.Oct 27, 2026
  3. Regulation FD DisclosureOct 21, 2026
  4. SCHEDULE 13D/A - filed by Roivant Sciences Ltd. regarding Arbutus Biopharma CorpOct 5, 2026
  5. 4 filingOct 5, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.